SMARCB1 and epithelioid sarcoma: The epithelioid sarcoma (for which tazemetostat has been approved by the FDA [26,27,28]) is deficient in the SMARCB1 (also known as INI1 or SNF5) subunit of the SWI/SNF family [27].